Compounds, including metal borate compounds, and electronic semiconducting devices including one or more of the compounds. Compounds may be used in a hole transport layer of the electronic semiconducting devices. Display devices, which may include a plurality of OLED pixels. The OLED pixels may include one or more compounds, including metal borate compounds.

The present invention relates to an electronic device comprising between a first electrode and a second electrode at least one first hole transport layer, wherein the first hole transport layer comprises (i) at least one first hole transport matrix compound consisting of covalently bound atoms and (ii) at least one electrical p-dopant selected from metal sate and from electrically neutral metal complexes comprising a metal cation and a at least one anion and/or at least one anionic ligand consisting of at least 4 covalently bound atoms, wherein the metal cation of the electrical p-dopant is selected from alkali metals; alkaline earth metals, Pb, Me, Fe, Co, Ni, Zn, Cd; rare earth metals in oxidation state (II) or (III); Al, Ga, In; and from Sn, Ti, Zr, Hf, V, Nb, Ta, Cr, Mo and W in oxidation state (TV) or less; provided that a) p-dopants comprising anion or anionic ligand having generic formula (Ia) or (Ib) wherein A.sup.1, A.sup.2, A.sup.3 and A.sup.4 are independently selected from CO, SO.sub.2 or POR.sup.1; R.sup.1=electron withdrawing group selected from the group comprising halide, nitrile, halogenated or perhalogenated C.sub.1 to C.sub.20 alkyl, halogenated or perhalogenated C.sub.6 to C.sub.20 aryl, or halogenated or perhalogenated heteroaryl with 5 to 20 ring-forming atoms; B.sup.1, B.sup.2, B.sup.3 and B.sup.4 are same or independently selected from substituted or unsubstituted C.sub.1 to C.sub.20 alkyl, substituted or unsubstituted C.sub.1 to C.sub.20 heteroalkyl, substituted or unsubstituted C.sub.6 to C.sub.20 aryl, substituted or unsubstituted C.sub.5 to C.sub.20 heteroaryl, or B.sup.1 and B.sup.2 form a ring; and b) p-dopants consisting of Li cation and an anion selected from perchlorate and tetrafluoroborate are excluded, and the first hole transport layer comprises a sublayer, wherein the electrical dopant is comprised in an amount, by weight and/or by volume, exceeding the total amount of other components which may additionally be comprised in the sublayer, and a method for preparing the same. ##STR00001##

The present invention relates to a cationic lipid having one or more biodegradable groups located in a lipidic moiety (e.g., a hydrophobic chain) of the cationic lipid. These cationic lipids may be incorporated into a lipid particle for delivering an active agent, such as a nucleic acid. The invention also relates to lipid particles comprising a neutral lipid, a lipid capable of reducing aggregation, a cationic lipid of the present invention, and optionally, a sterol. The lipid particle may further include a therapeutic agent such as a nucleic acid.

The compound represented by the following general formula is useful as a light emitting material. Ar.sup.1 represents an arylene group, Ar.sup.2 and Ar.sup.3 represent an aryl group, and R.sup.1 to R.sup.8 represent a hydrogen atom or a substituent, provided that at least one of R.sup.1 to R.sup.8 represents a diarylamino group. ##STR00001##

A nonaqueous electrolytic solution having an electrolyte salt dissolved in a nonaqueous solvent, the nonaqueous electrolytic solution containing a lithium salt having a specific α,β-dihydroxy carboxylic acid ester structure, phosphono hydroxy carboxylic acid structure, alkoxycarbonyl hydroxy carboxylic acid structure, or formyloxy structure; an energy storage device using the nonaqueous electrolytic solution; and a lithium salt used for the nonaqueous electrolytic solution. This nonaqueous electrolytic solution makes it possible not only to improve the electrochemical characteristics when the energy storage device is used at a high temperature and a high voltage and to improve the capacity retention rate after high-voltage and high-temperature storage, but also to suppress gas generation.

Disclosed are chemical entities of formula (I) wherein R.sub.1, R.sub.2 and n are defined herein, and methods of use thereof. These chemical entities are radiative emitters and are useful, e.g., as therapeutic agents for the treatment of, or as diagnostic (e.g., imaging) agents for cancers, e.g., cancers in which PARP1 is overexpressed.

##STR00001##

The present invention provides an optical purification layer, an edge-lit backlight module, and a polarizer. The material of the optical purification layer includes an organic absorbing dye for absorbing cyan light and yellow orange light having a wavelength range of 560-610 nm. The edge-lit backlight module includes a back plate, a reflector, a light guide plate, an edge light source, and an optical film module stacked, wherein the optical purification layer is provided between the edge light source and the light guide plate, or the optical purification layer is further provided between the light guide plate and the diffuse reflection layer, or the light guide plate includes a material of the optical purification layer.

The present patent application relates to new metal complexes having at least one N-aminoguanidinate ligand. The patent application further relates to the preparation of the new metal complexes and also to their use. The new metal complexes are especially suitable as precursors for the preparation of functional layers by means of gas-phase thin-film processes such as CVD, MO-CVD, MOVPE and ALD. Additionally, they are also suitable as catalysts for olefin hydroamination and for olefm polymerization.

##STR00001##

The present disclosure relates to a novel compound, a color conversion film, a backlight unit and a display device comprising the same.

The present invention provides a cycloyl formyl and cycloyl ketone compounds, a preparation method therefor, and a pharmaceutical use. The present invention finds that the compounds shown in formula (I) better inhibits Zika virus and dengue virus infection and replication, may be used as a drug for treating and preventing diseases caused by Zika virus and dengue virus, and may also become a drug for treating and preventing diseases caused by other flaviviruses, such as yellow fever, West Nile virus infection, Japanese encephalitis, AIDS caused by HIV etc., and diseases caused by hand, foot and mouth virus infection etc. The compounds may treat disease caused by bacterial infections, including inflammatory bowel disease ulcerative colitis and Crohn's disease, diseases caused by Escherichia coli, diseases caused by Staphylococcus aureus etc., and diseases caused by Acinetobacter baumannii.